BMY

Bristol-Myers Squibb Company

Healthcare
54.46 -0.49 -0.89% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 111.21B
EV —
Shares Out 2.04B
Revenue (ttm) 48.48B
Net Income 7.28B
Beta —
P/E 15.26
Forward P/E —
EPS (ttm) $3.57
P/S 2.29
P/B 5.53
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 8.03%
ROE 38.8%
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin 15.01%
Debt/Eq 2.41
LT Debt/Eq 67.75%
Quick Ratio —
Current Ratio 1.42
Book/sh 9.85
Cash/sh 4.7
Div Yield 4.59%
Div TTM $2.50
Payout Ratio 70.03%
SMA20 -4.49%
SMA50 -6.29%
SMA200 2.58%
Volume 13,739,876
Avg Volume 12.15M
Rel Volume —
Perf Week -4.76%
Perf Month -4.32%
Perf Quarter -10.34%
Perf Half Y 4.43%
Perf YTD 0.96%
Perf Year 13.84%
Perf 3Y -17.46%
Perf 5Y -16.14%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.6300
TTM Yield 4.59%
TTM Amount $2.50
Payout Ratio 70.03%
3-Yr Growth (CAGR) 4.37%
5-Yr Growth (CAGR) 6.24%

Last 12 Payouts

Period Ex-Date Amount / Share
Q1 2026 ~2026-03-31 $0.6300
Q4 2025 ~2025-12-30 $0.6300
Q3 2025 ~2025-09-30 $0.6200
Q2 2025 ~2025-06-30 $0.6200
Q1 2025 ~2025-03-31 $0.6200
Q4 2024 ~2024-12-30 $0.6200
Q3 2024 ~2024-09-30 $0.6000
Q2 2024 ~2024-06-30 $0.6000
Q1 2024 ~2024-03-31 $0.6000
Q4 2023 ~2023-12-30 $0.6000
Q3 2023 ~2023-09-30 $0.5700
Q2 2023 ~2023-06-30 $0.5700

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Bristol-Myers Squibb Company is a global biopharmaceutical company dedicated to transforming patients' lives through science. The company discovers, develops and delivers innovative medicines across multiple therapeutic areas including oncology, cardiovascular, immunology, cell therapy, and other disease areas. BMS operates through a portfolio consisting of Growth Brands (such as Opdivo, Orencia, Yervoy, Eliquis, and Camzyos) and Legacy Brands. The company's Growth Portfolio, which includes products earlier in their life cycles, delivered $26.4 billion in sales in 2025, marking a 17% increase over 2024. BMS has a diversified product portfolio addressing serious diseases and maintains a robust R&D pipeline with over 20 registrational assets. The company is committed to expanding patient access to its transformational medicines globally and maintaining financial discipline while investing in future growth drivers through strategic innovation and business development partnerships.

Name
Bristol-Myers Squibb Company
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner · Board Chair and Chief Executive Officer
Employees
—
IPO Date
2019-03-12
Phone
(609) 252-4621
Address
Route 206 & Province Line Road, Princeton, NJ 08543
Website
—

Key Executives

Name Title FY Pay
Julia A. Haller Director —
Deepak L. Bhatt Director —
Peter J. Arduini Director —
Theodore R. Samuels Lead Independent Director —
Christopher S. Boerner Board Chair and Chief Executive Officer —

Latest News